Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines by Mahapatro, Anil & Singh, Dinesh K
REVIEW Open Access
Biodegradable nanoparticles are excellent
vehicle for site directed in-vivo delivery of
drugs and vaccines
Anil Mahapatro
1 and Dinesh K Singh
2*
Abstract
Biodegradable nanoparticles (NPs) are gaining increased attention for their ability to serve as a viable carrier for site
specific delivery of vaccines, genes, drugs and other biomolecules in the body. They offer enhanced
biocompatibility, superior drug/vaccine encapsulation, and convenient release profiles for a number of drugs,
vaccines and biomolecules to be used in a variety of applications in the field of medicine. In this manuscript, the
methods of preparation of biodegradable NPs, different factors affecting optimal drug encapsulation, factors
affecting drug release rates, various surface modifications of nanoparticles to enhance in-vivo circulation,
distribution and multimodal functionalities along with the specific applications such as tumor targeting, oral
delivery, and delivery of these particles to the central nervous system have been reviewed.
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Review
Nanotechnology, although not a new concept, has
gained significant momentum in recent years. Due to
the recent advances in material science and nano-engi-
neering in the last decade, the nanoparticles have
become very attractive for their applications in the fields
of biology and medicine. Nanostructured materials are
materials with sizes in the 1-100 nm range, which
demonstrate unique properties and functions due to
their “size effect”[1]. Since most biologically active
macromolecules and agents such as viruses, membranes
and protein complexes are natural nanostructures [2], it
is assumed that nano-sized structures will be capable of
enhanced interaction with cell membrane and proteins.
The size and structure of nanoparticles also makes it
easier for these materials to be integrated in to a num-
ber of biomedical devices. Within past few years, rapid
developments have been made to use nanomaterials in a
wide variety of applications in various fields of medicine
such as cardiovascular and orthopedic. In medicine,
nanomaterials have been used in specific applications
such as tissue engineered scaffolds and devices, site spe-
cific drug delivery systems, cancer therapy and clinical
bioanalytical diagnostics and therapeutics [3-5]. In
recent years significant efforts have been made to use
nanotechnology for the purpose of drug and vaccine
delivery. The nanoparticles offer a suitable means to
deliver small molecular weight drugs as well as macro-
molecules such as proteins, peptides or genes in the
body using various routes of administration. The nano-
sized materials provide a mechanism for local or site
specific targeted delivery of macromolecules to the tis-
sue/organ of interest, in-vivo. The newer developments
in material science and nanoengineering are currently
being leveraged to formulate therapeutic agents in bio-
compatible nanocomposites such as nanoparticles, nano-
capsules, micellar systems and conjugates. In this
manuscript, we have reviewed preparation of polymer
based biodegradable nanoparticles and their applications
in the field of medicine.
Polymer-based nanoparticles are submicron-sized poly-
meric colloidal particles in which a therapeutic agent of
interest can be embedded or encapsulated within their
polymeric matrix or adsorbed or conjugated onto the sur-
face [6]. These nanoparticles serve as an excellent vehicle
for delivery of a number of biomolecules, drugs, genes
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1980’s and 1990’s several drug delivery systems were
developed to improve the efficiency of drugs and mini-
mize toxic side effects [7]. The early nanoparticles (NPs)
and microparticles were mainly formulated from poly-
alkyl-cyanoacrylate. The initial enthusiasm for the use of
microparticles in medicine was later on dampened due to
the size of the microparticles. There is a size limit for the
particles to be able to cross the intestinal mucosal barrier
of the gastrointestinal (GI) tract after the drug has been
delivered orally. Most often, macroparticles could not
cross mucosal barrier due to their bigger sizes resulting
in failed delivery of drugs. Nanoparticles on the other
hand have an advantage over microparticles due their
nano-sizes. They are also better suited for intravenous (i.
v.) delivery [8] compared to microparticles. Nanoparticles,
however, had a different set of problems of their own.
They had a very short circulating life span within the
body after intravenous administration. The nanoparticles
administered intravenously were rapidly cleared from the
body by phagocytic cells. The therapeutic effect of drugs
delivered via nanoparticles was thus minimized and could
not be sustained. In recent years the problem of phagocy-
tic removal of nanoparticles has been solved by surface
modification of nanoparticles [7]. The surface modifica-
tion protected nanoparticles from being phagocytosed
and removed from the blood vascular system after intra-
venous injections. Now, a wide variety of biomolecules,
vaccines and drugs can be delivered into the body using
nanoparticulate carriers and a number of routes of deliv-
ery. NPs can be used to safely and reliably deliver hydro-
philic drugs, hydrophobic drugs, proteins, vaccines, and
other biological macromolecules in the body. They can
be specifically designed for targeted drug delivery to the
brain, arterial walls, lungs, tumor cells, liver, and spleen.
They can also be designed for long-term systemic circula-
tion within the body. In addition, nanoparticles tagged
with imaging agents offer additional opportunities to
exploit optical imaging or MRI in cancer diagnosis and
guided hyperthermia therapy [9]. Figure 1 illustrates the
possibility of using a multimodal approach and integrated
systems that combine differing properties such as tumor
targeting, cancer therapy and imaging in an-all-in one
system [9]. Numerous techniques now exist for synthesiz-
ing different set of nanoparticles based on the type of
drugs used, and the targeted organ and delivery mechan-
ism selected. Depending upon the protocol of choice, the
parameters can be tailored to create the best possible
characteristics for the nanoparticles. In this manuscript
we have reviewed a number of biodegradable nanoparti-
cles currently in use, and the techniques of their prepara-
tion. We will also discuss advances in surface
modifications, drug encapsulation and specific end appli-
cations of various types of NPs.
Preparation of Nanoparticles
Biodegradable nanoparticles can be prepared from a vari-
ety of materials such as proteins, polysaccharides and
synthetic biodegradable polymers. The selection of the
base polymer is based on various designs and end appli-
cation criteria. It depends on many factors such as 1) size
of the desired nanoparticles, 2) properties of the drug
(aqueous solubility, stability, etc.) to be encapsulated in
the polymer, 3) surface characteristics and functionality,
4) degree of biodegradability and biocompatibility, and
5) drug release profile of the final product. Depending
upon selection of desired criteria for the preparation of
the nanoparticles, the methods can be classified as fol-
lowing 1) dispersion of preformed polymers, 2) polymeri-
zation of monomers and 3) ionic gelation method
for hydrophilic polymers. The general advantages and
disadvantages of individual methods are summarized in
Table 1[10].
Dispersion of preformed polymers
This is the most commonly used technique to prepare
biodegradable nanoparticles from poly-lactic acid (PLA);
poly -D- L-glycolide (PLG); poly-D- L-lactide-co-glyco-
lide (PLGA) and poly-cyanoacrylate (PCA). This techni-
que can be used in several ways as described below.
(a) Solvent evaporation method
In this technique the polymer is dissolved in an organic
solvent such as dichloromethane, chloroform or ethyl
acetate. The drug is dissolved or dispersed in the pre-
formed polymer solution followed by emulsification of
the mixture to form an oil/water (o/w) emulsion using
an appropriate surfactant/emulsifying agents. Most
Figure 1 Multifunctional nanoparticles. Multifunctional
nanoparticles can combine a specific targeting agent (usually with
an antibody or peptide) with nanoparticles for imaging (such as
quantum dots or magnetic nanoparticles), a cell-penetrating agent
(e.g., the polyArg peptide TAT), a stimulus-selective element for
drug release, a stabilizing polymer to ensure biocompatibility
polyethylene glycol most frequently), and the therapeutic
compound. Development of novel strategies for controlled released
of drugs will provide nanoparticles with the capability to deliver
two or more therapeutic agents. Adapted from ref [9] Copyright
2009 Wiley interscience.
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purpose are gelatin and polyvinyl alcohol. After forma-
tion of a stable emulsion the organic solvent is evapo-
rated by increasing the temperature or pressure along
with continuous stirring of the solution. Figure 2 shows
a schematic representation of this method [10]. Process
parameters such as stabilizer and polymer concentration
and stirring speed have a great influence on the particle
size of the NPs formed [8,11].
(b) Spontaneous emulsification/solvent diffusion method
This is a modified solvent diffusion method where a
water-miscible solvent such as acetone or methanol
along with a water-insoluble organic solvent such as
dichloromethane or chloroform are used as an oil phase
[12]. Due to the spontaneous diffusion of solvents, an
interfacial turbulence is created between the two phases
leading to the formation of smaller particles. As the
concentration of water- soluble solvent increases, smal-
ler particle sizes of NPs can be achieved [10,12].
(c) Nanoprecipitation method
Typically, this method is used for hydrophobic drug
entrapment, but it has been adapted for hydrophilic
drugs as well. Polymers and drugs are dissolved in a
polar, water-miscible solvent such as acetone, acetonitrile,
ethanol, or methanol. The solution is then poured in a
controlled manner (i.e. drop-by-drop addition) into an
aqueous solution with surfactant. Nanoparticles are
formed instantaneously by rapid solvent diffusion. Finally,
the solvent is removed under reduced pressure [13].
(d) Salting out method
In this method, the polymer is dissolved in the organic
phase, which should be water-miscible, like acetone or
tetrahydrofuran (THF). The organic phase is emulsified
in an aqueous phase, under strong mechanical shear
Table 1 Polymeric nanoparticles: general advantages and drawbacks of the various preparation methods (reproduced
from ref [10] with permission from Elsevier).
Method Simplicity of
Procedure
Need for
Purification
Facility Scaling-
up
EE (%) Safety of
Compounds
Polymerization of monomers
Emulsion polymerization
Organic Low High NR Low Low
Aqueous High High High High Medium
Interfacial polymerization Low High Medium High Low
Preformed polymers
Synthetic
Emulsification/solvent evaporation High Low Low Medium Medium
Solvent displacement and interfacial
deposition
High NR NR High Medium
Salting out High High High High Low
Emulsion/solvent diffusion Medium Medium High High Medium
Natural
Albumin NR High NR Medium Low
Gelatin NR High NR Medium Low
Polysaccharides
Alginate High Medium High High High
Chitosan High Medium High High High
Agarose Medium High NR NR High
Desolvation NR High NR Low Low
EE, Encapsulation Efficiency; NR, no reference available
Figure 2 Schematic representation of the emulsification-
evaporation technique. Adapted from ref [10] Copyright 2006
Elsevier.
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high concentration of salts which are not soluble in the
organic phase. Typically, the salts used are 60% w/w of
magnesium chloride hexahydrate [14] or magnesium
acetate tetrahydrate in 1:3 polymer to salt ratio [15].
Contrary to the emulsion diffusion method, there is no
diffusion of the solvent due to the presence of salts. The
fast addition of pure water to the o/w emulsion under
mild stirring reduces the ionic strength and leads to the
migration of the water-soluble organic solvent to the
aqueous phase inducing nanosphere formation. The
final step is purification of nanoparticles by cross flow
filtration or centrifugation to remove the salting out
agent [14,15].
Polymerization Methods
NPs are prepared from monomers that are polymerized
to form NPs in an aqueous solution. Vaccines or drugs/
therapeutic agents are incorporated in the NPs either by
dissolving the drug in the polymerization medium or by
adsorption/attachment of the drug onto the polymerized
and fully formed NPs. The NP suspension is then puri-
fied by removing stabilizers. The surfactants may be
recycled for subsequent polymerization. This technique
of NPs preparation has been reported for making poly-
butylcyanoacrylate or poly-alkyl-cyanoacrylate NPs
[16,17]. The concentration of surfactant and the stabili-
zer determines the final size of the NPs formed [18].
Ionic gelation method for hydrophilic polymers
Some of the natural macromolecules have been used to
prepare NPs. These polymers include gelatin, alginate,
chitosan and agarose. They are hydrophilic natural poly-
mers and have been used to synthesize biodegradable
N P sb yt h ei o n i cg e l a t i o nm ethod. This involves the
transition of materials from liquid to gel due to ionic
interaction at room temperature. An example of pre-
paration of gelatin NPs includes hardening of the dro-
plets of emulsified gelatin solution into gelatin NPs. The
gelatin emulsion droplets are cooled below the gelation
point in an ice bath leading to gelation of the droplets
[19] into gelatin NPs. Alginate NPs are reported to be
produced by drop-by-drop extrusion of the sodium algi-
nate solution into the calcium chloride solution [20].
Sodium alginate is a water-soluble polymer that gels in
the presence of multivalent cations such as calcium [21].
Chitosan NPs are prepared by spontaneous formation of
complexes between chitosan and polyanions or by the
gelation of a chitosan solution dispersed in an oil emul-
sion [22].
Biodegradable Nanoparticles
Biodegradable nanoparticles have been used for site-spe-
cific delivery of drugs, vaccines and various other
biomolecules. A few of the most extensively used biode-
gradable polymer matrices for preparation of nanoparti-
cles are:
Poly-D-L- lactide-co-glycolide (PLGA)
Poly-D-L- lactide-co-glycolide (PLGA) is one of the
most successfully used biodegradable polymers. It
undergoes hydrolysis in the body to produce biodegrad-
able metabolite monomers such as lactic acid and glyco-
lic acid. Figure 3 depicts the schematic representation of
the chemical structure of PLGA. Since lactic acid and
glycolic acids are normally found in the body and parti-
cipate in a number of physiological and biochemical
pathways, there is very minimal systemic toxicity asso-
ciated with the use of PLGA for the drug delivery or
biomaterial applications. PLGA NPs have been mostly
prepared by the emulsification-diffusion, the solvent eva-
poration and the nanoprecipitation methods [23]. PLGA
nanoparticles have been used to develop protein and
peptide based nanomedicines, nano-vaccines, and genes
containing nanoparticles for in-vivo delivery systems
[23,24].
Polylactic acid (PLA)
PLA (Figure 4) is a biocompatible and biodegradable
polymer which is broken down to monomeric units of
lactic acid in the body. Lactic acid is a natural inter-
mediate/by product of anaerobic respiration, which is
converted into glucose by the liver during the Cori
cycle. Glucose then is used as an energy source in the
body. The use of PLA nanoparticles is therefore safe
and devoid of any major toxicity. PLA nanoparticles
have been mostly prepared by the solvent evaporation,
solvent displacement, salting out and solvent diffusion
methods [10,25]. The salting out procedure is based on
the separation of a water- miscible solvent from aqueous
solution by adding a salting out agent like magnesium
chloride or calcium chloride. The main advantage of the
salting out procedure is that it minimizes stress to pro-
tein encapsulants [23].
Poly-ε-caprolactone (PCL)
poly-ε-caprolactone (Figure 5) is degraded by hydrolysis
of its ester linkages under the normal physiological
Figure 3 Structure of PLGA. The suffixes x and y represent the
number of lactic and glycolic acid respectively.
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toxicity. Therefore, PCL has grabbed the attention of
researchers as a candidate of choice for use in drug
delivery and long-term implantable devices. PCL’s
slower rate of degradation compared to polylactides has
made it better candidate for making long-term implan-
table devices. PCL nanoparticles have been prepared
mostly by nanoprecipitation, solvent displacement and
solvent evaporation [23,26,27].
Chitosan
Chitosan (Figure 6) is a modified natural carbohydrate
polymer prepared by the partial N-deacetylation of the
crustacean-derived natural biopolymer chitin. There are
at least four methods reported for the preparation of
chitosan nanoparticles. The four methods are ionotropic
gelation, microemulsion, emulsification solvent diffusion
and polyelectrolyte complex formation [23,28,29].
Gelatin
Gelatin (Figure 7) is extensively used in food and medi-
cal products and is a nontoxic alternative. Gelatin NPs
are very efficient in delivery and controlled release of
t h ed r u g s .T h e ya r en o n t o x i c ,b i o d e g r a d a b l e ,b i o a c t i v e
and inexpensive. Gelatin is a poly-ampholyte consisting
of both cationic and anionic groups along with a hydro-
philic group. It is known that the mechanical properties
such as swelling behavior and thermal properties of
gelatin NPs depend significantly on the degree of cross-
linking between cationic and anionic groups. These
properties of gelatin can be manipulated to prepare
desired type of NPs from gelatin. Gelatin nanoparticles
can be prepared by the desolvation/coacervation or
emulsion methods [23,30,31].
Poly-alkyl-cyano-acrylates (PAC)
The biodegradable as well as biocompatible poly-alkyl-
cyanoacrylates (Figure 8) are degraded by enzyme
esterases found in the body. On degradation they pro-
duce some toxic products that may stimulate or damage
the central nervous system. Thus this polymer is not
authorized for application in humans. PAC nanoparti-
cles are prepared mostly by emulsion polymerization,
interfacial polymerization and nanoprecipitation [10,23].
Surface Modification
One of the problems faced in the use of nanoparticles
via the intravenous route was their speedy removal by
the phagocytic cells (macrophages) in the body. Macro-
phages are powerful phagocytic cells and are the impor-
tant constituent of mononuclear phagocytic system
(MPS). The mononuclear phagocytic system (MPS) is
one of the body’s innate defenses. MPS filters and elimi-
nates any injected particulate matter including NPs
from the blood stream if they are recogniozed as foreign
body. Unless the injected nanoparticles are modified in
a way to escape recognition as foreign particles, they
will be phagocytosed and removed from the circulation.
This necessitated modification of the surface of nano-
particles in order for them to escape MPS recognition
and subsequent clearance. Surface modification of the
NPs therefore plays a critical role in their successful
applications in-vivo [32]. Once NPs are surface modified
with biomolecules found normally in the body, they will
be able to circulate within the blood vascular system for
longer period of time. This increases the probability of
Figure 4 Chemical structure of poly lactic acid (PLA).
Figure 5 Chemical structure of Poly-ε-caprolactone (PCL).
Figure 6 Chemical structure of chitosan.
Figure 7 Chemical structure of Gelatin.
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when compared to non- modified NPs. Smaller particles
(< 100 nm) circulating in blood vascular system with a
hydrophilic surface have the greatest ability to evade the
MPS [33,34]. Several methods have been developed for
surface modification of the NPs. The most preferred
method of surface modification is the adsorption or
grafting of poly-ethylene glycol (PEG) to the surface of
nanoparticles. Addition of PEG and PEG-containing
copolymers to the surface of nanoparticles results in an
increase in the blood circulation half-life of the particles.
The exact mechanisms by which PEG prolonged circula-
tion time of the surface modified NPs are still not well
understood. It is generally thought that the increased
residency of the nanoparticles in blood is mainly due to
prevention of opsonization of nanoparticles by a certain
serum or plasma proteins (opsonins). It is believed that
PEG causes steric repulsion by creating hydrated bar-
riers on nanoparticle surfaces that prevents coating of
PEG modified NPs by serum opsonins.
Studies have shown that the degree to which proteins
(opsonins) adsorb onto particle surface can be minimized
by increasing the PEG density on the particle surface.
Increasing the molecular weight of the PEG chains [33]
has also been shown to minimize opsonization of nano-
particles and improve retention in the circulation. For
example, Leroux et al. [35] showed that an increase in
PEG molecular weight was associated with less interac-
tion with the MPS, and longer systemic circulation of
PLGA nanoparticles. PEG has been shown to impart sta-
bility on PLA particles submerged in simulated gastric
fluid (SGF). Tobio et al. [36] showed that after 4 hours in
SGF, 9% of PLA nanoparticles converted to lactic acid
versus 3% conversion for PEG-PLA particles [36]. PEG is
also believed to facilitate mucoadhesion and consequent
transport through the Peyer’s patches of the GALT (gut
associated lymphoid tissue) [37]. In addition, PEG may
benefit nanoparticle’s interaction with blood constituents.
Thus, the presence of PEG on the nanoparticles imparts
additional functionality during the use of polymeric NPs.
Apart from PEG, there are other hydrophilic polymers
such as poloxamers, polysorbate 80, TPGS, polysorbate
20, polysaccharides like dextran and different type of
copolymers that can be used to efficiently coat conven-
tional nanoparticles to add number of variations in the
surface properties of NPs [38,39]. These coatings provide
a dynamic cloud of hydrophilic and neutral chains at the
particle surface, which repels plasma proteins. Surface
modification by TPGS increases the adhesion of nanopar-
ticles to tumor cell’s surfaces. It also provides safer envir-
onments to the encapsulated proteins. IgG coating on the
surface of nanoparticles increases the immunoresponse to
the encapsulated proteins within the nanoparticles.
Hydrophilic polymers can be applied at the surface of
NPs by adsorption of surfactants or by use of block copo-
lymers or branched copolymers [38-40].
Drug Loading and Encapsulation
One of the most desired qualities of a successful nano-
particle is its high loading capacity for the drugs. The
high loading ability of NPs reduces the amount of the
polymer carrier required for vaccine/drug delivery in the
body. The loading of drugs/vaccine into/onto nanoparti-
cles is achieved by two methods: 1) by incorporating the
drug at the time of nanoparticle production or 2) by
adsorbing the drug after the formation of nanoparticles.
Adsorption of drugs is achieved by incubating the NPs
in a concentrated drug solution [8]. These two methods
provide number of ways by which the drug is adsorbed/
attached to the NPs. The encapsulation of the drug in
the polymer, dispersion of the drug in the polymer,
adsorption of the drug onto the surface of the nanopar-
ticles and chemical binding of the drug to the polymer
can be accomplished using incorporation/adsorption
techniques. The amount of drugs bound to NPs and the
type of interaction -between drugs and nanoparticles
depend on the chemical structure of the drug, chemical
structure of the polymer and the conditions of drug
loading [41]. The amount of bound drug can be deter-
mined by subtracting the drug content in the superna-
tant from the primary amount of drug present in the
suspension.
The drug release mechanisms are an equally impor-
tant consideration during drug polymer formulation. It
will influence the effectiveness of the proposed applica-
tion and successful sustained drug delivery. In general,
the drug release rate depends on solubility of the drug,
desorption of the surface bound/adsorbed drug, drug
diffusion through the polymer matrix, NP matrix ero-
sion/degradation and combination of the erosion diffu-
sion process [23]. For manipulation of the drug release,
a good understanding of the mechanisms of drug release
is needed which would involve knowledge of the solubi-
lity, diffusion and biodegradation of the matrix. One
Figure 8 Chemical structure of Poly-alkyl-cyano-acrylates.
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appropriate polymer matrices. Drug release kinetics also
depend upon size of the NPs and the loading efficiency
of the vaccine or drug. The vaccine or drug loading effi-
ciency will determine the initial burst and the sustained
release rate of nanoencapsulated drug molecule. Larger
particles have a smaller initial burst release than smaller
particles. In the case of nanospheres, where the vaccine/
drug is uniformly distributed, the release occurs by dif-
fusion or erosion of the matrix under sink conditions. If
the diffusion of a vaccine/drug is faster than the matrix
erosion, the release mechanism is predominately
through a diffusion process. The rapid initial release or
burst of vaccine/drug seen in release profiles is mainly
attributed to weakly bound or adsorbed vaccine/drug on
to the surface [7,42].
Specific Applications of Biodegradable NPs
Tumor Targeting
The rationale of using nanoparticles for tumor targeting
i sb a s e do n1 )N P ’s ability to deliver the requisite dose
load of drug in the vicinity of the tumor due to the
enhanced permeability and retention effect or active tar-
geting by ligands on the surface of NPs and 2) NP’s abil-
ity to reduce the drug exposure to healthy tissues by
limiting drug distribution to the target organ. Active
tumor targeting of NPs may be achieved with either
direct targeting or the pretargeting method. In direct
targeting method NPs are covalently coupled with the
ligands. The ligand coupled NPs are received by the
tumor cells expressing a homologous receptor on their
surfaces. The specific ligand-receptor binding ensures
that the NPs carrying drugs will get attached specifically
to the tumor cells. This will facilitate delivery of drugs
only to the cells (tumor cells) expressing receptor and
not the normal healthy cells. In the pretargeting
approach, the therapeutic molecule is not coupled with
the ligand and is administered after an appropriate delay
time following the administration of the targeting ligand.
Nobs et al. [43] explored both-approaches to target PLA
NPs to tumor cells. In the direct approach, NPs with
mAbs exposed on their surface were incubated with the
two tumor cells, while in the pretargeting protocol,
tumor cells were pretargeted with biotinylated MABs
prior to the administration of avidin-labelled NPs [43].
Verdun et al. [44] in an elegant experiment demon-
strated positive effects of using poly- isohexylcyanoacry-
late-nanospheres in the delivery of doxorubicin in mice.
The doxorubicin incorporated into poly (isohexylcyanoa-
crylate) nanopsheres and delivered in mice showed
higher concentrations of doxorubicin in the liver, spleen
and the lungs than in mice treated with only free doxor-
ubicin [44]. Studies show that the drug distribution
pattern in the body is greatly influenced by selected
drug’s molecular weight, polymeric composition (type,
hydrophobicity and biodegradation profile) of nanoparti-
cles, localization of drug in the nanospheres, and drug
incorporation techniques such as adsorption or incor-
poration [45].
Extensive efforts have been devoted to achieving
“active targeting” of nanoparticles in order to deliver
drugs to the right targets. The molecular recognition
processes such as ligand-receptor specificity or antigen-
antibody interaction plays important role in such target-
ing. Considering that folate receptors are over expressed
on the surface of some human malignant cells and that
cell adhesion molecules such as selectins and integrins
are involved in metastatic events, nanoparticles bearing
specific ligands such as folate may be used to target
ovarian carcinoma while specific peptides or carbohy-
drates may be used to target integrins and selectins [46].
Oyewumi et al. [47] demonstrated that the benefits of
folate ligand coating were to facilitate internalization
and retention of Gd-nanoparticles in the tumor cells/tis-
sues [47]. Targeting with small ligands appears more
likely to succeed since they are easier to handle and
manufacture. Furthermore, it could be advantageous to
use active targeting ligands in combination with the
long-circulating nanoparticles to maximize the likeli-
hood of active targeting of nanoparticles.
Nanoparticles for Oral delivery
In recent years, significant research has been done using
nanoparticles as oral drug delivery vehicles. Oral deliv-
ery of drugs using nanoparticles has been shown to be
far superior to the delivery of free drugs in terms of
bioavialability, residence time, and biodistribution [48].
Advances in biotechnology and biochemistry have led to
the discovery of a large number of bioactive molecules
and vaccines based on peptides and proteins. Develop-
ment of suitable carriers remains a challenge due to the
fact that bioavailability of these molecules is limited by
the epithelial barriers of the gastrointestinal tract. The
drugs may also be susceptible to gastrointestinal degra-
dation by digestive enzymes. The advantage of using
polymeric nanoparticles is to allow encapsulation of
bioactive molecules and protect them against enzymatic
and hydrolytic degradation. For instance, it has been
found that insulin-loaded nanoparticles have preserved
insulin activity and produced blood glucose reduction in
diabetic rats for up to 14 days following the oral admin-
istration [49].
Another study showed that an antifungal drug encap-
sulated in particles of less than 300 nm in diameter was
detected in the lungs, liver, and spleen of mice seven
days post oral administration. The oral-free formulations
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administration [48]. For this application, the major
interest lies in lymphatic uptake of the nanoparticles by
the Peyer’s patches in the GALT (gut associated lym-
phoid tissue). There have been many reports as to the
optimum size for Peyer’s patch uptake ranging from less
than 1 μmt o5μm [50,51]. However, it has also been
shown that microparticles remain in the Peyer’s Patches
while nanoparticles are disseminated systemically [52,53]
Nanoparticles can be engineered not only for oral
absorption, but can also be used to deliver a drug
directly to the source for gastrointestinal uptake, thereby
protecting the drug from low pH and enzymes in the
stomach. The pH-sensitive nanoparticles made from a
poly(methylacrylic acid and methacyrlate) copolymer
can increase the oral bioavailability of drugs like cyclos-
porine-A by releasing their load at a specific pH within
the gastrointestinal tract. The pH sensitivity allows this
to happen as close as possible to the drug’s absorption
window through the Peyer’s patches [54].
Nanoparticles for vaccine/gene delivery
Polynucleotide vaccines/DNA vaccines/plasmid vaccines
work by delivering genes encoding relevant antigens to
host cells where they are expressed, producing the anti-
genic protein within the vicinity of professional antigen
presenting cells to initiate immune response. Such vac-
cines produce both humoral and cell-mediated immu-
nity because intracellular production of protein, as
opposed to extracellular deposition, stimulates both
arms of the immune system [55]. The key ingredient of
polynucleotide vaccines, DNA, can be produced cheaply
and has much better storage and handling properties
than the ingredients of the majority of protein-based
vaccines. Hence, polynucleotide vaccines/DNA vaccines
are set to supersede many conventional vaccines parti-
cularly for immunotherapy. However, there are several
issues related to the delivery of polynucleotides which
limit their application. These issues include efficient
delivery of the polynucleotide to the target cell popula-
tion, its localization to then u c l e u so ft h e s ec e l l s ,a n d
ensuring that the integrity of the polynucleotides is
maintained during delivery to the target site [2]. Nano-
particles loaded with plasmid DNA could also serve as
an efficient sustained release gene delivery system due
to their rapid escape from the degradative endo-lysoso-
mal compartment to the cytoplasmic compartment [56].
Hedley et al. [57] reported that following their intracel-
lular uptake and endolysosomal escape, nanoparticles
could release DNA at a sustained rate resulting in con-
tinuous gene expression. This gene delivery strategy
could be applied to facilitate bone healing by using
PLGA nanoparticles containing therapeutic genes such
as bone morphogenic protein.
Nanoparticles for drug delivery into the brain
The blood-brain barrier (BBB) is the most important
factor limiting the development of new drugs for the
central nervous system [58]. The BBB is characterized
by relatively impermeable endothelial cells with tight
junctions, enzymatic activitya n da c t i v ee f f l u xt r a n s p o r t
systems. It effectively prevents the passage of water-
soluble molecules from the blood circulation into the
CNS, and consequently only permits selective transport
of molecules that are essential for brain function [59].
Strategies for nanoparticle targeting to the brain rely on
nanoparticle’s interaction with the specific receptor-
mediated transport systems in the BBB. For example,
polysorbate 80/LDL, transferrin receptor binding anti-
body (such as OX26), lactoferrin, cell penetrating pep-
tides and melanotransferrin have been shown to be
capable of delivery of a self non transportable drug into
the brain via the chimeric construct that can undergo
receptor-mediated transcytosis [60-63]. It has been
reported that poly(butylcyanoacrylate) nanoparticles
were able to deliver hexapeptide dalargin, doxorubicin
and other agents into the brain which is significant
because of the great difficulty for drugs to cross the
BBB [62]. Despite some reported success with polysor-
bate 80 coated NPs, this system does have many short-
comings including desorption of polysorbate coating,
rapid NP degradation and toxicity caused by presence of
high concentration of polysorbate 80 [64]. OX26 MAbs
(anti-transferrin receptor MAbs), the most studied BBB
targeting antibody, have been used to enhance the BBB
penetration of lipsosomes [65].
Another study by Kreuter et al. [66] demonstrates the
delivery of several drugs successfully through the blood
brain barrier using polysorbate 80 coated PACA nano-
particles [66]. It is thought that after administration of
the polysorbate 80-coated particles, apolipoprotein E
(ApoE) adsorbs onto the surface. The ApoE protein
mimics low density lipoprotein (LDL) causing the parti-
cles to be transported across the blood brain barrier via
the LDL receptors. The effects of polysorbate-80 on
transport through the blood brain barrier were con-
firmed by Sun et al. with PLA nanoparticles [67]. Nano-
particles were also functionalized with thiamine surface
ligands. These particles, with an average diameter of 67
nm, were able to associate with the blood brain barrier
thiamine transporters and thereby increase the unidirec-
tional transfer coefficient for the particles into the brain
[68].
Conclusion
In summary, NPs are a potentially viable vaccine and
drug delivery system capable of delivering a multitude
of therapeutic agents and biomolecules at the targeted
sites in the body. To optimize NPs as a delivery system,
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Page 8 of 11greater understanding of the different mechanisms of
biological interactions and particle engineering is still
required. However, biodegradable NPs appear to be a
promising drug delivery carrier system because of their
versatile formulation, sustained release properties, sub
cellular size and biocompatibility with various cells and
tissue in the body.
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